05:17 AM EDT, 03/14/2025 (MT Newswires) -- Inovio Pharmaceuticals ( INO ) said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.

The company said all study participants "maintained biologically relevant levels of DMAbs" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.

The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca ( AZN ) , and clinical investigators at the University of Pennsylvania.